AGN

Algernon Pharmaceuticals to present findings of Ifenprodil study for treatment of idiopathic pulmonary fibrosis

Clinical stage Canadian drug development company Algernon Pharmaceuticals (CSE: AGN) will present the results of a phase 2a study into NP-120 (Ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough at next year’s American Cough Conference. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signalling. It […]